Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12439/3534
Title: A systematic review and Meta-Analysis ofMiddle meningeal artery embolization for Non-Acute Subdural Haematoma: A proposed treatment algorithm.
Northern Health Authors: Hong Kuan Kok�
Northern Health affiliation: (Kok) Interventional Radiology Service, Northern Imaging Victoria, Northern Health, Melbourne, Australia
(Kok) NECTAR Research Group, Northern Health, Melbourne, Australia
Authors: Edward Liu J.Barras C.D.Shaygi B.Kok H.K.Pavlin-Premrl D.Slater L.-A.Gan C.Gonzalvo A.Smith P.D.Russell J.Jhamb A.Moore J.Maingard J.Gauden A.Khabaza A.Chandra R.V.Yazdabadi A.Stevens S.Brooks M.Asadi H.
Citation: Journal of Clinical Neuroscience. 147(no pagination), 2026. Article Number: 111917. Date of Publication: 01 May 2026.
Issue Date: 1-May-2026
Abstract: Objective To synthesize the evidence from recent large randomized controlled trials (RCTs) on middle meningeal artery embolization (MMAE) for non-acute subdural haematoma (SDH) and to propose a unified, evidence-based treatment algorithm to guide clinical practice. Methods We conducted a systematic review and meta -analysis of large (n >= 100), multicentre RCTs comparing MMAE with surgical evacuation or conservative management for non-acute SDH. A comprehensive search of PubMed/MEDLINE, Embase, and CENTRAL was performed to August 2025. The primary outcome was treatment failure, a composite of radiological recurrence, symptomatic progression, or need for repeat surgery/surgical rescue at 90-180 days. Key secondary outcomes included functional status (modified Rankin Scale, mRS) and safety. Random-effects models were used for pooled analyses. Results Four RCTs involving 1,774 patients were included. For patients managed non-surgically, standalone MMAE was associated with a 64% relative risk reduction in treatment failure compared to conservative management (Risk Ratio [RR] 0.36, 95% CI [0.22, 0.60]). The number needed to treat was 4. As a surgical adjunct, MMAE offered a more modest but significant benefit in reducing recurrence or progression (RR 0.65, 95% CI [0.48, 0.89]). MMAE did not significantly improve functional outcomes or all-cause mortality but demonstrated a favourable safety profile with low rates of serious complications. Conclusions MMAE significantly reduces treatment failure in non-acute SDH, with the most profound benefit seen in non-surgical patients by lowering the need for surgical rescue. Its role as a routine surgical adjunct is less clear, suggesting a stratified approach for patients at high risk of recurrence.Copyright � 2026 The Author(s).
URI: https://hdl.handle.net/20.500.12439/3534
DOI: https://dx.doi.org/10.1016/j.jocn.2026.111917
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/41690054/
Type: Journal article
Study/Trial: Systematic review and/or meta-analysis
Access Rights: Open access
Place of publication: United Kingdom
Journal Title: Journal of Clinical Neuroscience
Appears in Collections:Articles

Show full item record

Page view(s)

70
checked on May 16, 2026

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.